{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:23:44Z","timestamp":1791685424501,"version":"4.3.4"},"reference-count":237,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00109-021-02174-z","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:03:55Z","timestamp":1642896235000},"page":"499-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Gaucher disease \u2013 more than just a rare lipid storage disease"],"prefix":"10.1007","volume":"100","author":[{"given":"Jaehyeok","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbaya","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-1539","authenticated-orcid":false,"given":"Reena V.","family":"Kartha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"key":"2174_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1083\/jcb.201607005","volume":"214","author":"CY Lim","year":"2016","unstructured":"Lim CY, Zoncu R (2016) The lysosome as a command-and-control center for cellular metabolism. J Cell Biol 214:653\u2013664. https:\/\/doi.org\/10.1083\/jcb.201607005","journal-title":"J Cell Biol"},{"key":"2174_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/tra.12056","volume":"14","author":"M Schwake","year":"2013","unstructured":"Schwake M, Schr\u00f6der B, Saftig P (2013) Lysosomal membrane proteins and their central role in physiology. Traffic 14:739\u2013748. https:\/\/doi.org\/10.1111\/tra.12056","journal-title":"Traffic"},{"key":"2174_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0005-2744(68)90251-9","volume":"159","author":"NJ Weinreb","year":"1968","unstructured":"Weinreb NJ, Brady RO, Tappel AL (1968) The lysosomal localization of sphingolipid hydrolases. Biochim Biophys Acta 159:141\u2013146. https:\/\/doi.org\/10.1016\/0005-2744(68)90251-9","journal-title":"Biochim Biophys Acta"},{"key":"2174_CR4","doi-asserted-by":"publisher","unstructured":"Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK (2021) Gaucher disease: basic and translational science needs for more complete therapy and management. Mol Genet Metab 132: 59-75. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.291","DOI":"10.1016\/j.ymgme.2020.12.291"},{"key":"2174_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-020-01520-7","volume":"15","author":"MM Andrade-Campos","year":"2020","unstructured":"Andrade-Campos MM, de Frutos LL, Cebolla JJ, Serrano-Gonzalo I, Medrano-Engay B, Roca-Espiau M, Gomez-Barrera B, P\u00e9rez-Heredia J, Iniguez D, Giraldo P (2020) Identification of risk features for complication in Gaucher\u2019s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis 15:256. https:\/\/doi.org\/10.1186\/s13023-020-01520-7","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","volume":"114","author":"TA Burrow","year":"2015","unstructured":"Burrow TA, Sun Y, Prada CE, Bailey L, Zhang W, Brewer A, Wu SW, Setchell KDR, Witte D, Cohen MB et al (2015) CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. Mol Genet Metab 114:233\u2013241. https:\/\/doi.org\/10.1016\/j.ymgme.2014.08.011","journal-title":"Mol Genet Metab"},{"key":"2174_CR7","doi-asserted-by":"publisher","unstructured":"Revel-Vilk S, Fuller M, Zimran A (2020) Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci 21.\u00a0https:\/\/doi.org\/10.3390\/ijms21197159","DOI":"10.3390\/ijms21197159"},{"key":"2174_CR8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/humu.22124","volume":"33","author":"I Bendikov-Bar","year":"2012","unstructured":"Bendikov-Bar I, Horowitz M (2012) Gaucher disease paradigm: from ERAD to comorbidity. Hum Mutat 33:1398\u20131407. https:\/\/doi.org\/10.1002\/humu.22124","journal-title":"Hum Mutat"},{"key":"2174_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM et al (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82:192\u2013207. https:\/\/doi.org\/10.1016\/j.ymgme.2004.04.011","journal-title":"Mol Genet Metab"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/1060028013500469","volume":"47","author":"LL Bennett","year":"2013","unstructured":"Bennett LL, Mohan D (2013) Gaucher disease and its treatment options. Ann Pharmacother 47:1182\u20131193. https:\/\/doi.org\/10.1177\/1060028013500469","journal-title":"Ann Pharmacother"},{"key":"2174_CR11","doi-asserted-by":"publisher","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A et al (2017) A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 18. https:\/\/doi.org\/10.3390\/ijms18020441","DOI":"10.3390\/ijms18020441"},{"key":"2174_CR12","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160:2835\u20132843. https:\/\/doi.org\/10.1001\/archinte.160.18.2835","journal-title":"Arch Intern Med"},{"key":"2174_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.beem.2014.08.007","volume":"29","author":"D Elstein","year":"2015","unstructured":"Elstein D, Alcalay R, Zimran A (2015) The emergence of Parkinson disease among patients with Gaucher disease. Best Pract Res Clin Endocrinol Metab 29:249\u2013259. https:\/\/doi.org\/10.1016\/j.beem.2014.08.007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2174_CR14","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/awq198","volume":"133","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, Mengel E, Mar\u00f3di L, Petakov M, Niederau C, Giraldo P, Hughes D, Mrsic M, Mehta A, Hollak CE et al (2010) Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 133:2909\u20132919. https:\/\/doi.org\/10.1093\/brain\/awq198","journal-title":"Brain"},{"key":"2174_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymgme.2013.04.001","volume":"109","author":"A McNeill","year":"2013","unstructured":"McNeill A, Roberti G, Lascaratos G, Hughes D, Mehta A, Garway-Heath DF, Schapira AH (2013) Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. Mol Genet Metab 109:221\u2013223. https:\/\/doi.org\/10.1016\/j.ymgme.2013.04.001","journal-title":"Mol Genet Metab"},{"key":"2174_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s004399900076","volume":"105","author":"H Ida","year":"1999","unstructured":"Ida H, Rennert OM, Iwasawa K, Kobayashi M, Eto Y (1999) Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet 105:120\u2013126. https:\/\/doi.org\/10.1007\/s004399900076","journal-title":"Hum Genet"},{"key":"2174_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/PHMT.S12499","volume":"2011","author":"BT Andrew","year":"2011","unstructured":"Andrew BT, Sonya B, Gregory G (2011) Prevalence and management of Gaucher disease. Pediatric Health, Medicine and Therapeutics 2011:59\u201373. https:\/\/doi.org\/10.2147\/PHMT.S12499","journal-title":"Pediatric Health, Medicine and Therapeutics"},{"key":"2174_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","volume":"4","author":"A Nagral","year":"2014","unstructured":"Nagral A (2014) Gaucher disease J Clin Exp Hepatol 4:37\u201350. https:\/\/doi.org\/10.1016\/j.jceh.2014.02.005","journal-title":"Gaucher disease J Clin Exp Hepatol"},{"key":"2174_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jmoldx.2017.05.005","volume":"19","author":"S Zampieri","year":"2017","unstructured":"Zampieri S, Cattarossi S, Bembi B, Dardis A (2017) GBA analysis in next-generation era: pitfalls, challenges, and possible solutions. J Mol Diagn 19:733\u2013741. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.05.005","journal-title":"J Mol Diagn"},{"key":"2174_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet 372:1263\u20131271. https:\/\/doi.org\/10.1016\/S0140-6736(08)61522-6","journal-title":"Lancet"},{"key":"2174_CR21","first-page":"99","volume":"12","author":"M Alaei","year":"2018","unstructured":"Alaei M, Jafari N, Rohani F, Ahmadabadi F, Azadi R (2018) Are there neurological symptoms in type 1 of Gaucher disease? Iran J Child Neurol 12:99\u2013106","journal-title":"Iran J Child Neurol"},{"key":"2174_CR22","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1038\/s41598-019-42584-1","volume":"9","author":"A \u0141ugowska","year":"2019","unstructured":"\u0141ugowska A, Hetma\u0144czyk-Sawicka K, Iwanicka-Nowicka R, Fogtman A, Cie\u015bla J, Purzycka-Olewiecka JK, Sitarska D, P\u0142oski R, Filocamo M, Lualdi S et al (2019) Gene expression profile in patients with Gaucher disease indicates activation of inflammatory processes. Sci Rep 9:6060. https:\/\/doi.org\/10.1038\/s41598-019-42584-1","journal-title":"Sci Rep"},{"key":"2174_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","volume":"33","author":"G Bultron","year":"2010","unstructured":"Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK (2010) The risk of Parkinson\u2019s disease in type 1 Gaucher disease. J Inherit Metab Dis 33:167\u2013173. https:\/\/doi.org\/10.1007\/s10545-010-9055-0","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp161","volume":"132","author":"Z Gan-Or","year":"2009","unstructured":"Gan-Or Z, Giladi N, Orr-Urtreger A (2009) Differential phenotype in Parkinson\u2019s disease patients with severe versus mild GBA mutations. Brain 132:e125. https:\/\/doi.org\/10.1093\/brain\/awp161","journal-title":"Brain"},{"key":"2174_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1212\/01.wnl.0000327823.81237.d1","volume":"72","author":"WC Nichols","year":"2009","unstructured":"Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T et al (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72:310\u2013316. https:\/\/doi.org\/10.1212\/01.wnl.0000327823.81237.d1","journal-title":"Neurology"},{"key":"2174_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M et al (2014) Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 71:752\u2013757. https:\/\/doi.org\/10.1001\/jamaneurol.2014.313","journal-title":"JAMA Neurol"},{"key":"2174_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10545-010-9095-5","volume":"33","author":"P Ch\u00e9rin","year":"2010","unstructured":"Ch\u00e9rin P, Rose C, de Roux-Serratrice C, Tardy D, Dobbelaere D, Grosbois B, Hachulla E, Jaussaud R, Javier RM, No\u00ebl E et al (2010) The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis 33:331\u2013338. https:\/\/doi.org\/10.1007\/s10545-010-9095-5","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/jimd.12182","volume":"43","author":"RV Kartha","year":"2020","unstructured":"Kartha RV, Joers J, Terluk MR, Travis A, Rudser K, Tuite PJ, Weinreb NJ, Jarnes JR, Cloyd JC, \u00d6z G (2020) Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy. J Inherit Metab Dis 43:564\u2013573. https:\/\/doi.org\/10.1002\/jimd.12182","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1089\/ars.2012.4720","volume":"18","author":"S Schiavone","year":"2013","unstructured":"Schiavone S, Jaquet V, Trabace L, Krause KH (2013) Severe life stress and oxidative stress in the brain: from animal models to human pathology. Antioxid Redox Signal 18:1475\u20131490. https:\/\/doi.org\/10.1089\/ars.2012.4720","journal-title":"Antioxid Redox Signal"},{"issue":"Suppl 1","key":"2174_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jnc.13670","volume":"139","author":"DM Vogt Weisenhorn","year":"2016","unstructured":"Vogt Weisenhorn DM, Giesert F, Wurst W (2016) Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson\u2019s Disease. J Neurochem 139(Suppl 1):8\u201326. https:\/\/doi.org\/10.1111\/jnc.13670","journal-title":"J Neurochem"},{"key":"2174_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/bies.201500124","volume":"38","author":"H Dueck","year":"2016","unstructured":"Dueck H, Eberwine J, Kim J (2016) Variation is function: are single cell differences functionally important?: testing the hypothesis that single cell variation is required for aggregate function. BioEssays 38:172\u2013180. https:\/\/doi.org\/10.1002\/bies.201500124","journal-title":"BioEssays"},{"key":"2174_CR32","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1101\/gad.13.10.1211","volume":"13","author":"RJ Kaufman","year":"1999","unstructured":"Kaufman RJ (1999) Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 13:1211\u20131233. https:\/\/doi.org\/10.1101\/gad.13.10.1211","journal-title":"Genes Dev"},{"key":"2174_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek D, Schwake M, Schr\u00f6der J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131:770\u2013783. https:\/\/doi.org\/10.1016\/j.cell.2007.10.018","journal-title":"Cell"},{"key":"2174_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm2199","volume":"8","author":"D Ron","year":"2007","unstructured":"Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8:519\u2013529. https:\/\/doi.org\/10.1038\/nrm2199","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2174_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","volume":"74","author":"M Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der M, Kaufman RJ (2005) The mammalian unfolded protein response. Annu Rev Biochem 74:739\u2013789. https:\/\/doi.org\/10.1146\/annurev.biochem.73.011303.074134","journal-title":"Annu Rev Biochem"},{"key":"2174_CR36","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.biocel.2012.03.004","volume":"44","author":"Z Jian","year":"2012","unstructured":"Jian Z, Li JB, Ma RY, Chen L, Wang XF, Xiao YB (2012) Pivotal role of activating transcription factor 6\u03b1 in myocardial adaptation to chronic hypoxia. Int J Biochem Cell Biol 44:972\u2013979. https:\/\/doi.org\/10.1016\/j.biocel.2012.03.004","journal-title":"Int J Biochem Cell Biol"},{"key":"2174_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature07203","volume":"454","author":"K Zhang","year":"2008","unstructured":"Zhang K, Kaufman RJ (2008) From endoplasmic-reticulum stress to the inflammatory response. Nature 454:455\u2013462. https:\/\/doi.org\/10.1038\/nature07203","journal-title":"Nature"},{"key":"2174_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbrc.2011.08.080","volume":"413","author":"YJ Lee","year":"2011","unstructured":"Lee YJ, Kim SJ, Heo TH (2011) Protective effect of catechin in type I Gaucher disease cells by reducing endoplasmic reticulum stress. Biochem Biophys Res Commun 413:254\u2013258. https:\/\/doi.org\/10.1016\/j.bbrc.2011.08.080","journal-title":"Biochem Biophys Res Commun"},{"key":"2174_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bcmd.2016.10.025","volume":"68","author":"H Braunstein","year":"2018","unstructured":"Braunstein H, Maor G, Chicco G, Filocamo M, Zimran A, Horowitz M (2018) UPR activation and CHOP mediated induction of GBA1 transcription in Gaucher disease. Blood Cells Mol Dis 68:21\u201329. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.025","journal-title":"Blood Cells Mol Dis"},{"key":"2174_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1750-1172-8-140","volume":"8","author":"G Maor","year":"2013","unstructured":"Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M (2013) Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J Rare Dis 8:140. https:\/\/doi.org\/10.1186\/1750-1172-8-140","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069147","volume":"8","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Shimoda M, Ito K, Hanai S, Aizawa H, Kato T, Kawasaki K, Yamaguchi T, Ryoo HD, Goto-Inoue N et al (2013) Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS ONE 8:e69147. https:\/\/doi.org\/10.1371\/journal.pone.0069147","journal-title":"PLoS ONE"},{"key":"2174_CR42","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.cellsig.2014.03.026","volume":"26","author":"M Li","year":"2014","unstructured":"Li M, Liu Y, Xia F, Wu Z, Deng L, Jiang R, Guo FJ (2014) Progranulin is required for proper ER stress response and inhibits ER stress-mediated apoptosis through TNFR2. Cell Signal 26:1539\u20131548. https:\/\/doi.org\/10.1016\/j.cellsig.2014.03.026","journal-title":"Cell Signal"},{"key":"2174_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ebiom.2016.08.004","volume":"11","author":"J Jian","year":"2016","unstructured":"Jian J, Zhao S, Tian QY, Liu H, Zhao Y, Chen WC, Grunig G, Torres PA, Wang BC, Zeng B et al (2016) Association between progranulin and Gaucher disease. EBioMedicine 11:127\u2013137. https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.004","journal-title":"EBioMedicine"},{"key":"2174_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ebiom.2016.10.010","volume":"13","author":"J Jian","year":"2016","unstructured":"Jian J, Tian QY, Hettinghouse A, Zhao S, Liu H, Wei J, Grunig G, Zhang W, Setchell KDR, Sun Y et al (2016) Progranulin recruits HSP70 to \u03b2-glucocerebrosidase and is therapeutic against Gaucher disease. EBioMedicine 13:212\u2013224. https:\/\/doi.org\/10.1016\/j.ebiom.2016.10.010","journal-title":"EBioMedicine"},{"key":"2174_CR45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/humu.23056","volume":"37","author":"M Horowitz","year":"2016","unstructured":"Horowitz M, Elstein D, Zimran A, Goker-Alpan O (2016) New directions in Gaucher disease. Hum Mutat 37:1121\u20131136. https:\/\/doi.org\/10.1002\/humu.23056","journal-title":"Hum Mutat"},{"key":"2174_CR46","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/hmg\/ddw129","volume":"25","author":"G Maor","year":"2016","unstructured":"Maor G, Cabasso O, Krivoruk O, Rodriguez J, Steller H, Segal D, Horowitz M (2016) The contribution of mutant GBA to the development of Parkinson disease in Drosophila. Hum Mol Genet 25:2712\u20132727. https:\/\/doi.org\/10.1093\/hmg\/ddw129","journal-title":"Hum Mol Genet"},{"key":"2174_CR47","doi-asserted-by":"publisher","unstructured":"Chong WC, Shastri MD, Eri R (2017) Endoplasmic reticulum stress and oxidative stress: a vicious nexus implicated in bowel disease pathophysiology. Int J Mol Sci 18. https:\/\/doi.org\/10.3390\/ijms18040771","DOI":"10.3390\/ijms18040771"},{"key":"2174_CR48","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.bbamcr.2013.02.007","volume":"1833","author":"OB Oka","year":"2013","unstructured":"Oka OB, Bulleid NJ (2013) Forming disulfides in the endoplasmic reticulum. Biochim Biophys Acta 1833:2425\u20132429. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.02.007","journal-title":"Biochim Biophys Acta"},{"key":"2174_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.freeradbiomed.2015.02.019","volume":"83","author":"A Delaunay-Moisan","year":"2015","unstructured":"Delaunay-Moisan A, Appenzeller-Herzog C (2015) The antioxidant machinery of the endoplasmic reticulum: protection and signaling. Free Radic Biol Med 83:341\u2013351. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.02.019","journal-title":"Free Radic Biol Med"},{"key":"2174_CR50","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1373\/clinchem.2006.067793","volume":"52","author":"R Rossi","year":"2006","unstructured":"Rossi R, Dalle-Donne I, Milzani A, Giustarini D (2006) Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress. Clin Chem 52:1406\u20131414. https:\/\/doi.org\/10.1373\/clinchem.2006.067793","journal-title":"Clin Chem"},{"key":"2174_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.redox.2015.07.012","volume":"6","author":"B Schmitt","year":"2015","unstructured":"Schmitt B, Vicenzi M, Garrel C, Denis FM (2015) Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol 6:198\u2013205. https:\/\/doi.org\/10.1016\/j.redox.2015.07.012","journal-title":"Redox Biol"},{"key":"2174_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100667","volume":"25","author":"RV Kartha","year":"2020","unstructured":"Kartha RV, Terluk MR, Brown R, Travis A, Mishra UR, Rudser K, Lau H, Jarnes JR, Cloyd JC, Weinreb NJ (2020) Patients with Gaucher disease display systemic oxidative stress dependent on therapy status. Mol Genet Metab Rep 25:100667. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100667","journal-title":"Mol Genet Metab Rep"},{"key":"2174_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nbd.2015.09.006","volume":"90","author":"ME Gegg","year":"2016","unstructured":"Gegg ME, Schapira AH (2016) Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol Dis 90:43\u201350. https:\/\/doi.org\/10.1016\/j.nbd.2015.09.006","journal-title":"Neurobiol Dis"},{"key":"2174_CR54","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Wong YC, Gao F, Krainc D (2021) Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson\u2019s disease. Nat Commun 12:1807. https:\/\/doi.org\/10.1038\/s41467-021-22113-3","journal-title":"Nat Commun"},{"key":"2174_CR55","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1073\/pnas.1910854117","volume":"117","author":"C King","year":"2020","unstructured":"King C, Sengupta P, Seo AY, Lippincott-Schwartz J (2020) ER membranes exhibit phase behavior at sites of organelle contact. Proc Natl Acad Sci U S A 117:7225\u20137235. https:\/\/doi.org\/10.1073\/pnas.1910854117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2174_CR56","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1038\/s41467-019-12152-2","volume":"10","author":"D H\u00f6glinger","year":"2019","unstructured":"H\u00f6glinger D, Burgoyne T, Sanchez-Heras E, Hartwig P, Colaco A, Newton J, Futter CE, Spiegel S, Platt FM, Eden ER (2019) NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress. Nat Commun 10:4276. https:\/\/doi.org\/10.1038\/s41467-019-12152-2","journal-title":"Nat Commun"},{"key":"2174_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","volume":"62","author":"MW Cleeter","year":"2013","unstructured":"Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, Wood NW, Hardy J, Mark Cooper J, Schapira AH (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 62:1\u20137. https:\/\/doi.org\/10.1016\/j.neuint.2012.10.010","journal-title":"Neurochem Int"},{"key":"2174_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","volume":"15","author":"H Li","year":"2019","unstructured":"Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, Ko HS, Quan Y, Sardi SP, Li A et al (2019) Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy 15:113\u2013130. https:\/\/doi.org\/10.1080\/15548627.2018.1509818","journal-title":"Autophagy"},{"key":"2174_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210617","volume":"14","author":"MM Ivanova","year":"2019","unstructured":"Ivanova MM, Changsila E, Iaonou C, Goker-Alpan O (2019) Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. PLoS ONE 14:e0210617. https:\/\/doi.org\/10.1371\/journal.pone.0210617","journal-title":"PLoS ONE"},{"key":"2174_CR60","unstructured":"Demaurex N, Frieden M, Arnaudeau S (2000\u20132013) ER calcium and ER chaperones: new players in apoptosis? Landes Bioscience, Austin (TX)"},{"key":"2174_CR61","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10545-017-0048-0","volume":"40","author":"A Saffari","year":"2017","unstructured":"Saffari A, K\u00f6lker S, Hoffmann GF, Ebrahimi-Fakhari D (2017) Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases. J Inherit Metab Dis 40:631\u2013640. https:\/\/doi.org\/10.1007\/s10545-017-0048-0","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR62","doi-asserted-by":"publisher","unstructured":"Costa CAD, Manaa WE, Duplan E, Checler F (2020) The endoplasmic reticulum stress\/unfolded protein response and their contributions to Parkinson\u2019s disease physiopathology. Cells 9. https:\/\/doi.org\/10.3390\/cells9112495","DOI":"10.3390\/cells9112495"},{"key":"2174_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/sj.onc.1210638","volume":"27","author":"A Deniaud","year":"2008","unstructured":"Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C, Brenner C (2008) Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27:285\u2013299. https:\/\/doi.org\/10.1038\/sj.onc.1210638","journal-title":"Oncogene"},{"key":"2174_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.nbd.2004.09.004","volume":"18","author":"D Pelled","year":"2005","unstructured":"Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH (2005) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 18:83\u201388. https:\/\/doi.org\/10.1016\/j.nbd.2004.09.004","journal-title":"Neurobiol Dis"},{"key":"2174_CR65","doi-asserted-by":"publisher","first-page":"21673","DOI":"10.1074\/jbc.274.31.21673","volume":"274","author":"E Korkotian","year":"1999","unstructured":"Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem 274:21673\u201321678. https:\/\/doi.org\/10.1074\/jbc.274.31.21673","journal-title":"J Biol Chem"},{"key":"2174_CR66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.tibs.2016.09.001","volume":"41","author":"A Raffaello","year":"2016","unstructured":"Raffaello A, Mammucari C, Gherardi G, Rizzuto R (2016) Calcium at the center of cell signaling: interplay between endoplasmic reticulum, mitochondria, and lysosomes. Trends Biochem Sci 41:1035\u20131049. https:\/\/doi.org\/10.1016\/j.tibs.2016.09.001","journal-title":"Trends Biochem Sci"},{"key":"2174_CR67","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1089\/ars.2006.8.1391","volume":"8","author":"A G\u00f6rlach","year":"2006","unstructured":"G\u00f6rlach A, Klappa P, Kietzmann T (2006) The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal 8:1391\u20131418. https:\/\/doi.org\/10.1089\/ars.2006.8.1391","journal-title":"Antioxid Redox Signal"},{"key":"2174_CR68","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41418-019-0442-2","volume":"27","author":"N Plotegher","year":"2020","unstructured":"Plotegher N, Perocheau D, Ferrazza R, Massaro G, Bhosale G, Zambon F, Rahim AA, Guella G, Waddington SN, Szabadkai G et al (2020) Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload. Cell Death Differ 27:1588\u20131603. https:\/\/doi.org\/10.1038\/s41418-019-0442-2","journal-title":"Cell Death Differ"},{"key":"2174_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fncel.2014.00213","volume":"8","author":"N Chaudhari","year":"2014","unstructured":"Chaudhari N, Talwar P, Parimisetty A, Lefebvre d\u2019Hellencourt C, Ravanan P (2014) A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci 8:213. https:\/\/doi.org\/10.3389\/fncel.2014.00213","journal-title":"Front Cell Neurosci"},{"key":"2174_CR70","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1016\/j.celrep.2018.11.064","volume":"25","author":"P Atakpa","year":"2018","unstructured":"Atakpa P, Thillaiappan NB, Mataragka S, Prole DL, Taylor CW (2018) IP3 receptors preferentially associate with ER-lysosome contact sites and selectively deliver Ca2+ to lysosomes. Cell Rep 25:3180-3193.e3187. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.064","journal-title":"Cell Rep"},{"key":"2174_CR71","doi-asserted-by":"publisher","first-page":"19266","DOI":"10.1073\/pnas.2003236117","volume":"117","author":"W Peng","year":"2020","unstructured":"Peng W, Wong YC, Krainc D (2020) Mitochondria-lysosome contacts regulate mitochondrial Ca. Proc Natl Acad Sci U S A 117:19266\u201319275. https:\/\/doi.org\/10.1073\/pnas.2003236117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2174_CR72","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1093\/hmg\/ddw322","volume":"25","author":"B Liou","year":"2016","unstructured":"Liou B, Peng Y, Li R, Inskeep V, Zhang W, Quinn B, Dasgupta N, Blackwood R, Setchell KD, Fleming S et al (2016) Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Hum Mol Genet 25:5126\u20135141. https:\/\/doi.org\/10.1093\/hmg\/ddw322","journal-title":"Hum Mol Genet"},{"key":"2174_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fneur.2018.00295","volume":"9","author":"V Ghiglieri","year":"2018","unstructured":"Ghiglieri V, Calabrese V, Calabresi P (2018) Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol 9:295. https:\/\/doi.org\/10.3389\/fneur.2018.00295","journal-title":"Front Neurol"},{"key":"2174_CR74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bbrc.2007.04.108","volume":"358","author":"M Nakai","year":"2007","unstructured":"Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, Ohtaka-Maruyama C, Okado H, Hashimoto M (2007) Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson\u2019s disease, in erythropoietic lineage. Biochem Biophys Res Commun 358:104\u2013110. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.108","journal-title":"Biochem Biophys Res Commun"},{"key":"2174_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","volume":"373","author":"I Stojkovska","year":"2018","unstructured":"Stojkovska I, Krainc D, Mazzulli JR (2018) Molecular mechanisms of \u03b1-synuclein and GBA1 in Parkinson\u2019s disease. Cell Tissue Res 373:51\u201360. https:\/\/doi.org\/10.1007\/s00441-017-2704-y","journal-title":"Cell Tissue Res"},{"key":"2174_CR76","doi-asserted-by":"publisher","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC (2018) Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb Perspect Med 8. https:\/\/doi.org\/10.1101\/cshperspect.a024091","DOI":"10.1101\/cshperspect.a024091"},{"key":"2174_CR77","doi-asserted-by":"publisher","unstructured":"Faustini G, Bono F, Valerio A, Pizzi M, Spano P, Bellucci A (2017) Mitochondria and \u03b1-synuclein: friends or foes in the pathogenesis of Parkinson\u2019s disease? Genes (Basel) 8. https:\/\/doi.org\/10.3390\/genes8120377","DOI":"10.3390\/genes8120377"},{"key":"2174_CR78","doi-asserted-by":"publisher","unstructured":"Lin KJ, Lin KL, Chen SD, Liou CW, Chuang YC, Lin HY, Lin TK (2019) The overcrowded crossroads: mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson\u2019s disease. Int J Mol Sci 20. https:\/\/doi.org\/10.3390\/ijms20215312","DOI":"10.3390\/ijms20215312"},{"key":"2174_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neulet.2008.05.005","volume":"439","author":"S Shavali","year":"2008","unstructured":"Shavali S, Brown-Borg HM, Ebadi M, Porter J (2008) Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett 439:125\u2013128. https:\/\/doi.org\/10.1016\/j.neulet.2008.05.005","journal-title":"Neurosci Lett"},{"key":"2174_CR80","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1523\/JNEUROSCI.2507-13.2014","volume":"34","author":"C Guardia-Laguarta","year":"2014","unstructured":"Guardia-Laguarta C, Area-Gomez E, R\u00fcb C, Liu Y, Magran\u00e9 J, Becker D, Voos W, Schon EA, Przedborski S (2014) \u03b1-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci 34:249\u2013259. https:\/\/doi.org\/10.1523\/JNEUROSCI.2507-13.2014","journal-title":"J Neurosci"},{"key":"2174_CR81","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1093\/hmg\/ddu105","volume":"23","author":"YH Xu","year":"2014","unstructured":"Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, Xue L, Zhang W, Setchell KD, Witte D et al (2014) Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet 23:3943\u20133957. https:\/\/doi.org\/10.1093\/hmg\/ddu105","journal-title":"Hum Mol Genet"},{"key":"2174_CR82","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","volume":"1822","author":"L Breydo","year":"2012","unstructured":"Breydo L, Wu JW, Uversky VN (2012) \u0391-synuclein misfolding and Parkinson\u2019s disease. Biochim Biophys Acta 1822:261\u2013285. https:\/\/doi.org\/10.1016\/j.bbadis.2011.10.002","journal-title":"Biochim Biophys Acta"},{"key":"2174_CR83","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1615\/critrevoncog.2013004503","volume":"18","author":"MK Pandey","year":"2013","unstructured":"Pandey MK, Grabowski GA (2013) Immunological cells and functions in Gaucher disease. Crit Rev Oncog 18:197\u2013220. https:\/\/doi.org\/10.1615\/critrevoncog.2013004503","journal-title":"Crit Rev Oncog"},{"key":"2174_CR84","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","volume":"27","author":"C Auffray","year":"2009","unstructured":"Auffray C, Sieweke MH, Geissmann F (2009) Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27:669\u2013692. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132557","journal-title":"Annu Rev Immunol"},{"key":"2174_CR85","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev.immunol.26.021607.090326","volume":"26","author":"NV Serbina","year":"2008","unstructured":"Serbina NV, Jia T, Hohl TM, Pamer EG (2008) Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 26:421\u2013452. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090326","journal-title":"Annu Rev Immunol"},{"key":"2174_CR86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10. QJM 90:19\u201325. https:\/\/doi.org\/10.1093\/qjmed\/90.1.19","journal-title":"QJM"},{"key":"2174_CR87","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00277-008-0441-8","volume":"87","author":"M de Fost","year":"2008","unstructured":"de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG, Aerts JF, Maas M, Vom Dahl S et al (2008) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87:439\u2013449. https:\/\/doi.org\/10.1007\/s00277-008-0441-8","journal-title":"Ann Hematol"},{"key":"2174_CR88","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1073\/pnas.1200941109","volume":"109","author":"J Liu","year":"2012","unstructured":"Liu J, Halene S, Yang M, Iqbal J, Yang R, Mehal WZ, Chuang WL, Jain D, Yuen T, Sun L et al (2012) Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci U S A 109:10018\u201310023. https:\/\/doi.org\/10.1073\/pnas.1200941109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2174_CR89","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1172\/JCI14530","volume":"109","author":"H Mizukami","year":"2002","unstructured":"Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, Werth N, Sandhoff R, Sandhoff K, Proia RL (2002) Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 109:1215\u20131221. https:\/\/doi.org\/10.1172\/JCI14530","journal-title":"J Clin Invest"},{"key":"2174_CR90","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","volume":"1772","author":"MJ van Breemen","year":"2007","unstructured":"van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772:788\u2013796. https:\/\/doi.org\/10.1016\/j.bbadis.2007.04.002","journal-title":"Biochim Biophys Acta"},{"key":"2174_CR91","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21:677\u2013687. https:\/\/doi.org\/10.1038\/nm.3893","journal-title":"Nat Med"},{"key":"2174_CR92","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.imbio.2008.11.007","volume":"214","author":"C Eder","year":"2009","unstructured":"Eder C (2009) Mechanisms of interleukin-1beta release. Immunobiology 214:543\u2013553. https:\/\/doi.org\/10.1016\/j.imbio.2008.11.007","journal-title":"Immunobiology"},{"key":"2174_CR93","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/acel.12409","volume":"15","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, Marugan J, Patnaik S, Maniwang E, Gonzalez AN et al (2016) Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell 15:77\u201388. https:\/\/doi.org\/10.1111\/acel.12409","journal-title":"Aging Cell"},{"key":"2174_CR94","volume-title":"Immunobiology: the immune system in health and disease, 5th","author":"CAJ Janeway","year":"2001","unstructured":"Janeway CAJ, Travers P, Walport M, Shlomchik MJ (2001) Immunobiology: the immune system in health and disease, 5th, edition. Garland Science, New York","edition":"edition"},{"key":"2174_CR95","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1124\/pr.111.005223","volume":"65","author":"A Klos","year":"2013","unstructured":"Klos A, Wende E, Wareham KJ, Monk PN (2013) International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 65:500\u2013543. https:\/\/doi.org\/10.1124\/pr.111.005223","journal-title":"Pharmacol Rev"},{"key":"2174_CR96","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature21368","volume":"543","author":"MK Pandey","year":"2017","unstructured":"Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B et al (2017) Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543:108\u2013112. https:\/\/doi.org\/10.1038\/nature21368","journal-title":"Nature"},{"key":"2174_CR97","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nri3761","volume":"14","author":"M Kolev","year":"2014","unstructured":"Kolev M, Le Friec G, Kemper C (2014) Complement\u2013tapping into new sites and effector systems. Nat Rev Immunol 14:811\u2013820. https:\/\/doi.org\/10.1038\/nri3761","journal-title":"Nat Rev Immunol"},{"key":"2174_CR98","doi-asserted-by":"publisher","unstructured":"Kalluri R, LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367. https:\/\/doi.org\/10.1126\/science.aau6977","DOI":"10.1126\/science.aau6977"},{"key":"2174_CR99","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.201211138","volume":"200","author":"G Raposo","year":"2013","unstructured":"Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373\u2013383. https:\/\/doi.org\/10.1083\/jcb.201211138","journal-title":"J Cell Biol"},{"key":"2174_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","volume":"19","author":"S Gurung","year":"2021","unstructured":"Gurung S, Perocheau D, Touramanidou L, Baruteau J (2021) The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal 19:47. https:\/\/doi.org\/10.1186\/s12964-021-00730-1","journal-title":"Cell Commun Signal"},{"key":"2174_CR101","doi-asserted-by":"publisher","unstructured":"Ciferri MC, Quarto R, Tasso R (2021) Extracellular vesicles as biomarkers and therapeutic tools: from pre-clinical to clinical applications. Biology (Basel) 10.\u00a0https:\/\/doi.org\/10.3390\/biology10050359","DOI":"10.3390\/biology10050359"},{"key":"2174_CR102","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41596-019-0126-x","volume":"14","author":"H Zhang","year":"2019","unstructured":"Zhang H, Lyden D (2019) Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat Protoc 14:1027\u20131053. https:\/\/doi.org\/10.1038\/s41596-019-0126-x","journal-title":"Nat Protoc"},{"key":"2174_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201800149","volume":"19","author":"BD Chan","year":"2019","unstructured":"Chan BD, Wong WY, Lee MM, Cho WC, Yee BK, Kwan YW, Tai WC (2019) Exosomes in inflammation and inflammatory disease. Proteomics 19:e1800149. https:\/\/doi.org\/10.1002\/pmic.201800149","journal-title":"Proteomics"},{"key":"2174_CR104","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.trecan.2020.03.007","volume":"6","author":"VS LeBleu","year":"2020","unstructured":"LeBleu VS, Kalluri R (2020) Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer 6:767\u2013774. https:\/\/doi.org\/10.1016\/j.trecan.2020.03.007","journal-title":"Trends Cancer"},{"key":"2174_CR105","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12951-021-00879-4","volume":"19","author":"L Guo","year":"2021","unstructured":"Guo L, Huang Z, Huang L, Liang J, Wang P, Zhao L, Shi Y (2021) Surface-modified engineered exosomes attenuated cerebral ischemia\/reperfusion injury by targeting the delivery of quercetin towards impaired neurons. J Nanobiotechnology 19:141. https:\/\/doi.org\/10.1186\/s12951-021-00879-4","journal-title":"J Nanobiotechnology"},{"key":"2174_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2020.104038","volume":"63","author":"S Tatiana","year":"2020","unstructured":"Tatiana S, Stanislav N, Darya K, Luiza G, Konstantin S, Sergey L, Elena V, Galina S, Nikolai V, Arthur K et al (2020) Altered level of plasma exosomes in patients with Gaucher disease. Eur J Med Genet 63:104038. https:\/\/doi.org\/10.1016\/j.ejmg.2020.104038","journal-title":"Eur J Med Genet"},{"key":"2174_CR107","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/hmg\/ddy075","volume":"27","author":"VE Papadopoulos","year":"2018","unstructured":"Papadopoulos VE, Nikolopoulou G, Antoniadou I, Karachaliou A, Arianoglou G, Emmanouilidou E, Sardi SP, Stefanis L, Vekrellis K (2018) Modulation of \u03b2-glucocerebrosidase increases \u03b1-synuclein secretion and exosome release in mouse models of Parkinson\u2019s disease. Hum Mol Genet 27:1696\u20131710. https:\/\/doi.org\/10.1093\/hmg\/ddy075","journal-title":"Hum Mol Genet"},{"key":"2174_CR108","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1038\/ncomms5755","volume":"5","author":"EJ Bae","year":"2014","unstructured":"Bae EJ, Yang NY, Song M, Lee CS, Lee JS, Jung BC, Lee HJ, Kim S, Masliah E, Sardi SP et al (2014) Glucocerebrosidase depletion enhances cell-to-cell transmission of \u03b1-synuclein. Nat Commun 5:4755. https:\/\/doi.org\/10.1038\/ncomms5755","journal-title":"Nat Commun"},{"key":"2174_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ymgme.2019.10.006","volume":"129","author":"PH Johnson","year":"2020","unstructured":"Johnson PH, Weinreb NJ, Cloyd JC, Tuite PJ, Kartha RV (2020) GBA1 mutations: prospects for exosomal biomarkers in \u03b1-synuclein pathologies. Mol Genet Metab 129:35\u201346. https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.006","journal-title":"Mol Genet Metab"},{"key":"2174_CR110","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fncel.2018.00125","volume":"12","author":"S Cerri","year":"2018","unstructured":"Cerri S, Ghezzi C, Sampieri M, Siani F, Avenali M, Dornini G, Zangaglia R, Minafra B, Blandini F (2018) The exosomal\/total \u03b1-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients. Front Cell Neurosci 12:125. https:\/\/doi.org\/10.3389\/fncel.2018.00125","journal-title":"Front Cell Neurosci"},{"key":"2174_CR111","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1074\/jbc.M114.585703","volume":"290","author":"M Grey","year":"2015","unstructured":"Grey M, Dunning CJ, Gaspar R, Grey C, Brundin P, Sparr E, Linse S (2015) Acceleration of \u03b1-synuclein aggregation by exosomes. J Biol Chem 290:2969\u20132982. https:\/\/doi.org\/10.1074\/jbc.M114.585703","journal-title":"J Biol Chem"},{"key":"2174_CR112","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.bbadis.2015.08.010","volume":"1852","author":"K Essandoh","year":"2015","unstructured":"Essandoh K, Yang L, Wang X, Huang W, Qin D, Hao J, Wang Y, Zingarelli B, Peng T, Fan GC (2015) Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. Biochim Biophys Acta 1852:2362\u20132371. https:\/\/doi.org\/10.1016\/j.bbadis.2015.08.010","journal-title":"Biochim Biophys Acta"},{"key":"2174_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1684","volume":"13","author":"I Abasolo","year":"2021","unstructured":"Abasolo I, Seras-Franzoso J, Molt\u00f3-Abad M, D\u00edaz-Riascos V, Corchero JL, Pintos-Morell G, Schwartz S (2021) Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 13:e1684. https:\/\/doi.org\/10.1002\/wnan.1684","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"Suppl 1","key":"2174_CR114","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","volume":"75","author":"RJ Wenstrup","year":"2002","unstructured":"Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(Suppl 1):A2-12. https:\/\/doi.org\/10.1259\/bjr.75.suppl_1.750002","journal-title":"Br J Radiol"},{"key":"2174_CR115","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3109\/08820139.2013.822766","volume":"42","author":"PP Souza","year":"2013","unstructured":"Souza PP, Lerner UH (2013) The role of cytokines in inflammatory bone loss. Immunol Invest 42:555\u2013622. https:\/\/doi.org\/10.3109\/08820139.2013.822766","journal-title":"Immunol Invest"},{"key":"2174_CR116","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/192761","volume":"2015","author":"JM Mucci","year":"2015","unstructured":"Mucci JM, Rozenfeld P (2015) Pathogenesis of bone alterations in Gaucher disease: the role of immune system. J Immunol Res 2015:192761. https:\/\/doi.org\/10.1155\/2015\/192761","journal-title":"J Immunol Res"},{"key":"2174_CR117","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymgme.2020.07.011","volume":"132","author":"PA Rozenfeld","year":"2021","unstructured":"Rozenfeld PA, Crivaro AN, Ormazabal M, Mucci JM, Bondar C, Delpino MV (2021) Unraveling the mystery of Gaucher bone density pathophysiology. Mol Genet Metab 132:76\u201385. https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.011","journal-title":"Mol Genet Metab"},{"key":"2174_CR118","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/clp.13.78","volume":"9","author":"JM Mucci","year":"2014","unstructured":"Mucci JM, Rozenfeld PA (2014) Examining the impact of bone pathology on type I Gaucher disease. Clinical Lipidology 9:61\u201370. https:\/\/doi.org\/10.2217\/clp.13.78","journal-title":"Clinical Lipidology"},{"key":"2174_CR119","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1152\/physrev.00036.2016","volume":"97","author":"K Okamoto","year":"2017","unstructured":"Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A, Sawa S, Nitta T, Takayanagi H (2017) Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev 97:1295\u20131349. https:\/\/doi.org\/10.1152\/physrev.00036.2016","journal-title":"Physiol Rev"},{"key":"2174_CR120","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201\u2013212. https:\/\/doi.org\/10.1006\/bcmd.1997.0137","journal-title":"Blood Cells Mol Dis"},{"key":"2174_CR121","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.micres.2011.02.005","volume":"167","author":"Y Xu","year":"2011","unstructured":"Xu Y, Yang F, Liu Y, Wang Z, Wang J, Wang G, Li R (2011) Genetic diversity of Microcystis populations in a bloom and its relationship to the environmental factors in Qinhuai River, China. Microbiol Res 167:20\u201326. https:\/\/doi.org\/10.1016\/j.micres.2011.02.005","journal-title":"Microbiol Res"},{"key":"2174_CR122","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2164-12-20","volume":"12","author":"YH Xu","year":"2011","unstructured":"Xu YH, Jia L, Quinn B, Zamzow M, Stringer K, Aronow B, Sun Y, Zhang W, Setchell KD, Grabowski GA (2011) Global gene expression profile progression in Gaucher disease mouse models. BMC Genomics 12:20. https:\/\/doi.org\/10.1186\/1471-2164-12-20","journal-title":"BMC Genomics"},{"key":"2174_CR123","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D et al (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195\u20132202","journal-title":"Blood"},{"key":"2174_CR124","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.1400768111","volume":"111","author":"PK Mistry","year":"2014","unstructured":"Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J et al (2014) Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A 111:4934\u20134939. https:\/\/doi.org\/10.1073\/pnas.1400768111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2174_CR125","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/284836","volume":"2014","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Chen B, Yan F, Guo J, Zhu X, Ma S, Yang W (2014) Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int 2014:284836. https:\/\/doi.org\/10.1155\/2014\/284836","journal-title":"Biomed Res Int"},{"key":"2174_CR126","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1442-200X.2007.02502.x","volume":"49","author":"M Yoshino","year":"2007","unstructured":"Yoshino M, Watanabe Y, Tokunaga Y, Harada E, Fujii C, Numata S, Harada M, Tajima A, Ida H (2007) Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr Int 49:959\u2013965. https:\/\/doi.org\/10.1111\/j.1442-200X.2007.02502.x","journal-title":"Pediatr Int"},{"key":"2174_CR127","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/jbmr.1680","volume":"27","author":"A Khan","year":"2012","unstructured":"Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK (2012) Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J Bone Miner Res 27:1839\u20131848. https:\/\/doi.org\/10.1002\/jbmr.1680","journal-title":"J Bone Miner Res"},{"key":"2174_CR128","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","volume":"179","author":"M Maas","year":"2002","unstructured":"Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ (2002) Quantification of skeletal involvement in adults with type I Gaucher\u2019s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179:961\u2013965. https:\/\/doi.org\/10.2214\/ajr.179.4.1790961","journal-title":"AJR Am J Roentgenol"},{"key":"2174_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.108851","volume":"125","author":"D Li","year":"2020","unstructured":"Li D, Tao X, Zhang N, Huo A, Kang H, Xu C, Zhang Y, Peng Y (2020) Do magnetic resonance imaging manifestations of skeletal system improve after treatment of Gaucher disease? Eur J Radiol 125:108851. https:\/\/doi.org\/10.1016\/j.ejrad.2020.108851","journal-title":"Eur J Radiol"},{"key":"2174_CR130","doi-asserted-by":"crossref","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ (2009) Avascular necrosis in untreated patients with type 1 Gaucher disease blood","DOI":"10.1182\/blood.V114.22.1353.1353"},{"key":"2174_CR131","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2106\/00004623-198668090-00011","volume":"68","author":"RS Bell","year":"1986","unstructured":"Bell RS, Mankin HJ, Doppelt SH (1986) Osteomyelitis in Gaucher disease. J Bone Joint Surg Am 68:1380\u20131388","journal-title":"J Bone Joint Surg Am"},{"key":"2174_CR132","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Solano V, P\u00e9rez-Calvo JI, Giralt M, Rubio-F\u00e9lix D, disease SGoG (2005) Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 14:453\u2013462. https:\/\/doi.org\/10.1007\/s11136-004-0794-y","journal-title":"Qual Life Res"},{"key":"2174_CR133","first-page":"37","volume":"65","author":"KF Lutsky","year":"2007","unstructured":"Lutsky KF, Tejwani NC (2007) Orthopaedic manifestations of Gaucher disease. Bull NYU Hosp Jt Dis 65:37\u201342","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2174_CR134","doi-asserted-by":"publisher","unstructured":"Binnetoglu E, Komurcu E, Sen H, Kizildag B (2013) Gaucher disease with pathological femoral neck fracture. BMJ Case Rep 2013. https:\/\/doi.org\/10.1136\/bcr-2013-200260","DOI":"10.1136\/bcr-2013-200260"},{"key":"2174_CR135","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3858\/emm.2010.42.5.039","volume":"42","author":"JM Hong","year":"2010","unstructured":"Hong JM, Kim TH, Kim HJ, Park EK, Yang EK, Kim SY (2010) Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head. Exp Mol Med 42:376\u2013385. https:\/\/doi.org\/10.3858\/emm.2010.42.5.039","journal-title":"Exp Mol Med"},{"key":"2174_CR136","doi-asserted-by":"publisher","first-page":"157","DOI":"10.11138\/ccmbm\/2015.12.2.157","volume":"12","author":"S Linari","year":"2015","unstructured":"Linari S, Castaman G (2015) Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab 12:157\u2013164. https:\/\/doi.org\/10.11138\/ccmbm\/2015.12.2.157","journal-title":"Clin Cases Miner Bone Metab"},{"key":"2174_CR137","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2147\/JIR.S281941","volume":"13","author":"SB Goodman","year":"2020","unstructured":"Goodman SB, Maruyama M (2020) Inflammation, bone healing and osteonecrosis: from bedside to bench. J Inflamm Res 13:913\u2013923. https:\/\/doi.org\/10.2147\/JIR.S281941","journal-title":"J Inflamm Res"},{"key":"2174_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2011.1.1","volume":"2011","author":"T Schmidt","year":"2011","unstructured":"Schmidt T, Carmeliet P (2011) Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program 2011:1\u20138. https:\/\/doi.org\/10.1182\/asheducation-2011.1.1","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2174_CR139","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","volume":"10","author":"NJ Weinreb","year":"2015","unstructured":"Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, Amato D (2015) Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Rare Dis 10:64. https:\/\/doi.org\/10.1186\/s13023-015-0280-3","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR140","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","volume":"89","author":"O Neudorfer","year":"1996","unstructured":"Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A (1996) Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease. QJM 89:691\u2013694. https:\/\/doi.org\/10.1093\/qjmed\/89.9.691","journal-title":"QJM"},{"key":"2174_CR141","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b","volume":"61","author":"M Machaczka","year":"1999","unstructured":"Machaczka M, Rucinska M, Skotnicki AB, Jurczak W (1999) Parkinson\u2019s syndrome preceding clinical manifestation of Gaucher\u2019s disease. Am J Hematol 61:216\u2013217. https:\/\/doi.org\/10.1002\/(sici)1096-8652(199907)61:3%3c216::aid-ajh12%3e3.0.co;2-b","journal-title":"Am J Hematol"},{"key":"2174_CR142","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/mgme.2001.3201","volume":"73","author":"N Tayebi","year":"2001","unstructured":"Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, Fillano JJ, Sidransky E (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73:313\u2013321. https:\/\/doi.org\/10.1006\/mgme.2001.3201","journal-title":"Mol Genet Metab"},{"key":"2174_CR143","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajmg.a.10028","volume":"116A","author":"J V\u00e1rkonyi","year":"2003","unstructured":"V\u00e1rkonyi J, Rosenbaum H, Baumann N, MacKenzie JJ, Simon Z, Aharon-Peretz J, Walker JM, Tayebi N, Sidransky E (2003) Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet A 116A:348\u2013351. https:\/\/doi.org\/10.1002\/ajmg.a.10028","journal-title":"Am J Med Genet A"},{"key":"2174_CR144","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000072482.70963.d7","volume":"61","author":"B Bembi","year":"2003","unstructured":"Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, Martini C, Gioulis M, Pittis MG, Capus L (2003) Gaucher\u2019s disease with Parkinson\u2019s disease: clinical and pathological aspects. Neurology 61:99\u2013101. https:\/\/doi.org\/10.1212\/01.wnl.0000072482.70963.d7","journal-title":"Neurology"},{"key":"2174_CR145","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa033277","volume":"351","author":"J Aharon-Peretz","year":"2004","unstructured":"Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med 351:1972\u20131977. https:\/\/doi.org\/10.1056\/NEJMoa033277","journal-title":"N Engl J Med"},{"key":"2174_CR146","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","volume":"81","author":"A Lwin","year":"2004","unstructured":"Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 81:70\u201373. https:\/\/doi.org\/10.1016\/j.ymgme.2003.11.004","journal-title":"Mol Genet Metab"},{"key":"2174_CR147","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mcn.2015.03.013","volume":"66","author":"AH Schapira","year":"2015","unstructured":"Schapira AH (2015) Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 66:37\u201342. https:\/\/doi.org\/10.1016\/j.mcn.2015.03.013","journal-title":"Mol Cell Neurosci"},{"key":"2174_CR148","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361:1651\u20131661. https:\/\/doi.org\/10.1056\/NEJMoa0901281","journal-title":"N Engl J Med"},{"key":"2174_CR149","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/mdc3.13031","volume":"7","author":"E Ryan","year":"2020","unstructured":"Ryan E, Amato D, MacKenzie JJ, Sidransky E, Lopez G (2020) Parkinsonism in Patients with neuronopathic (type 3) Gaucher disease: a case series. Mov Disord Clin Pract 7:834\u2013837. https:\/\/doi.org\/10.1002\/mdc3.13031","journal-title":"Mov Disord Clin Pract"},{"key":"2174_CR150","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrneurol.2010.52","volume":"6","author":"AH Schapira","year":"2010","unstructured":"Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6:309\u2013317. https:\/\/doi.org\/10.1038\/nrneurol.2010.52","journal-title":"Nat Rev Neurol"},{"key":"2174_CR151","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D (2011) Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37\u201352. https:\/\/doi.org\/10.1016\/j.cell.2011.06.001","journal-title":"Cell"},{"key":"2174_CR152","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","volume":"24","author":"GH Kim","year":"2015","unstructured":"Kim GH, Kim JE, Rhie SJ, Yoon S (2015) The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 24:325\u2013340. https:\/\/doi.org\/10.5607\/en.2015.24.4.325","journal-title":"Exp Neurobiol"},{"key":"2174_CR153","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnagi.2010.00012","volume":"2","author":"X Wang","year":"2010","unstructured":"Wang X, Michaelis EK (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2:12. https:\/\/doi.org\/10.3389\/fnagi.2010.00012","journal-title":"Front Aging Neurosci"},{"key":"2174_CR154","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10571-015-0157-y","volume":"35","author":"ME Ferreira","year":"2015","unstructured":"Ferreira ME, de Vasconcelos AS, da Costa VT, da Silva TL, da Silva BA, Gomes AR, Dolabela MF, Perc\u00e1rio S (2015) Oxidative stress in Alzheimer\u2019s disease: should we keep trying antioxidant therapies? Cell Mol Neurobiol 35:595\u2013614. https:\/\/doi.org\/10.1007\/s10571-015-0157-y","journal-title":"Cell Mol Neurobiol"},{"key":"2174_CR155","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrn2038","volume":"8","author":"ML Block","year":"2007","unstructured":"Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57\u201369. https:\/\/doi.org\/10.1038\/nrn2038","journal-title":"Nat Rev Neurosci"},{"key":"2174_CR156","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fnana.2015.00091","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson\u2019s disease. Front Neuroanat 9:91. https:\/\/doi.org\/10.3389\/fnana.2015.00091","journal-title":"Front Neuroanat"},{"key":"2174_CR157","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74:995\u20131002. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d5a4a3","journal-title":"Neurology"},{"key":"2174_CR158","doi-asserted-by":"publisher","unstructured":"Rachsee A, Chiranthanut N, Kunnaja P, Sireeratawong S, Khonsung P, Chansakaow S, Panthong A (2021) Mucuna pruriens (L.) DC. seed extract inhibits lipopolysaccharide-induced inflammatory responses in BV2 microglial cells. J Ethnopharmacol 267:113518. https:\/\/doi.org\/10.1016\/j.jep.2020.113518","DOI":"10.1016\/j.jep.2020.113518"},{"key":"2174_CR159","doi-asserted-by":"publisher","unstructured":"Javed H, Meeran MFN, Azimullah S, Bader Eddin L, Dwivedi VD, Jha NK, Ojha S (2020) \u03b1-Bisabolol, a dietary bioactive phytochemical attenuates dopaminergic neurodegeneration through modulation of oxidative stress, neuroinflammation and apoptosis in rotenone-induced rat model of Parkinson\u2019s disease. Biomolecules 10. https:\/\/doi.org\/10.3390\/biom10101421","DOI":"10.3390\/biom10101421"},{"key":"2174_CR160","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1042\/CS20200553","volume":"134","author":"Y Tian","year":"2020","unstructured":"Tian Y, Cao Y, Chen R, Jing Y, Xia L, Zhang S, Xu H, Su Z (2020) HMGB1 a box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson\u2019s disease model. Clin Sci (Lond) 134:2075\u20132090. https:\/\/doi.org\/10.1042\/CS20200553","journal-title":"Clin Sci (Lond)"},{"key":"2174_CR161","doi-asserted-by":"publisher","unstructured":"Egger F, Jakab M, Fuchs J, Oberascher K, Brachtl G, Ritter M, Kerschbaum HH, Gaisberger M (2020) Effect of glycine on BV-2 microglial cells treated with interferon-\u03b3 and lipopolysaccharide. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21030804","DOI":"10.3390\/ijms21030804"},{"key":"2174_CR162","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen X, Hu Y, Cao Z, Liu Q, Cheng Y (2018) Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer\u2019s disease, Parkinson\u2019s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol 9:2122. https:\/\/doi.org\/10.3389\/fimmu.2018.02122","journal-title":"Front Immunol"},{"key":"2174_CR163","doi-asserted-by":"publisher","unstructured":"Galper J, Balwani M, Fahn S, Waters C, Krohn L, Gan-Or Z, Dzamko N, Alcalay RN (2021) Cytokines and Gaucher biomarkers in glucocerebrosidase carriers with and without Parkinson disease. Mov Disord. https:\/\/doi.org\/10.1002\/mds.28525","DOI":"10.1002\/mds.28525"},{"key":"2174_CR164","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ene.13837","volume":"26","author":"S Mullin","year":"2019","unstructured":"Mullin S, Hughes D, Mehta A, Schapira AHV (2019) Neurological effects of glucocerebrosidase gene mutations. Eur J Neurol 26:388-e329. https:\/\/doi.org\/10.1111\/ene.13837","journal-title":"Eur J Neurol"},{"key":"2174_CR165","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1073\/pnas.1321845111","volume":"111","author":"P Vald\u00e9s","year":"2014","unstructured":"Vald\u00e9s P, Mercado G, Vidal RL, Molina C, Parsons G, Court FA, Martinez A, Galleguillos D, Armentano D, Schneider BL et al (2014) Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc Natl Acad Sci U S A 111:6804\u20136809. https:\/\/doi.org\/10.1073\/pnas.1321845111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2174_CR166","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A (2011) How I treat Gaucher disease Blood 118:1463\u20131471. https:\/\/doi.org\/10.1182\/blood-2011-04-308890","journal-title":"How I treat Gaucher disease Blood"},{"key":"2174_CR167","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE (1991) Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med 324:1464\u20131470. https:\/\/doi.org\/10.1056\/NEJM199105233242104","journal-title":"N Engl J Med"},{"key":"2174_CR168","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10545-011-9285-9","volume":"34","author":"XS Zhang","year":"2011","unstructured":"Zhang XS, Brondyk W, Lydon JT, Thurberg BL, Piepenhagen PA (2011) Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. J Inherit Metab Dis 34:795\u2013809. https:\/\/doi.org\/10.1007\/s10545-011-9285-9","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR169","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/S0140-6736(96)04451-0","volume":"348","author":"PK Mistry","year":"1996","unstructured":"Mistry PK, Wraight EP, Cox TM (1996) Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher\u2019s disease. Lancet 348:1555\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(96)04451-0","journal-title":"Lancet"},{"key":"2174_CR170","doi-asserted-by":"publisher","unstructured":"Beutler E, Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BE (1991) Enzyme-replacement therapy for Gaucher\u2019s disease. New England J Medicine 325:1809\u20131811. https:\/\/doi.org\/10.1056\/nejm199112193252513","DOI":"10.1056\/nejm199112193252513"},{"key":"2174_CR171","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1586\/17446651.2014.887434","volume":"9","author":"BE Rosenbloom","year":"2014","unstructured":"Rosenbloom BE, Weinreb NJ (2014) Bone disease in patients with Gaucher disease. Expert Rev Endocrinol Metab 9:153\u2013162. https:\/\/doi.org\/10.1586\/17446651.2014.887434","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2174_CR172","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","volume":"96","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96:470\u2013476. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.d01-2076.x","journal-title":"Br J Haematol"},{"key":"2174_CR173","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-319-57613-8_4","volume":"1003","author":"C Sturtzel","year":"2017","unstructured":"Sturtzel C (2017) Endothelial Cells. Adv Exp Med Biol 1003:71\u201391. https:\/\/doi.org\/10.1007\/978-3-319-57613-8_4","journal-title":"Adv Exp Med Biol"},{"key":"2174_CR174","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nri2171","volume":"7","author":"JS Pober","year":"2007","unstructured":"Pober JS, Sessa WC (2007) Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7:803\u2013815. https:\/\/doi.org\/10.1038\/nri2171","journal-title":"Nat Rev Immunol"},{"key":"2174_CR175","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3892\/etm.2021.9677","volume":"21","author":"Y Oto","year":"2021","unstructured":"Oto Y, Inoue T, Nagai S, Tanaka S, Itabashi H, Shiraisihi M, Nitta A, Murakami N, Ida H, Matsubara T (2021) Successful treatment of Gaucher disease type 1 by enzyme replacement therapy over a 10-year duration in a Japanese pediatric patient: a case report. Exp Ther Med 21:246. https:\/\/doi.org\/10.3892\/etm.2021.9677","journal-title":"Exp Ther Med"},{"key":"2174_CR176","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.11406\/rinketsu.61.1654","volume":"61","author":"C Matsubara","year":"2020","unstructured":"Matsubara C, Yamamoto K, Maeda T, Itakura J, Uehara T, Shiote Y, Adachi K, Kamoi C, Oyama T, Shiraishi Y et al (2020) Successful treatment with enzyme replacement therapy for pelvic fragile fracture in an elderly case of type I Gaucher\u2019s disease. Rinsho Ketsueki 61:1654\u20131659. https:\/\/doi.org\/10.11406\/rinketsu.61.1654","journal-title":"Rinsho Ketsueki"},{"key":"2174_CR177","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17512433.2018.1549486","volume":"11","author":"P Gupta","year":"2018","unstructured":"Gupta P, Pastores G (2018) Pharmacological treatment of pediatric Gaucher disease. Expert Rev Clin Pharmacol 11:1183\u20131194. https:\/\/doi.org\/10.1080\/17512433.2018.1549486","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2174_CR178","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/bjh.15402","volume":"182","author":"S Revel-Vilk","year":"2018","unstructured":"Revel-Vilk S, Szer J, Mehta A, Zimran A (2018) How we manage Gaucher disease in the era of choices. Br J Haematol 182:467\u2013480. https:\/\/doi.org\/10.1111\/bjh.15402","journal-title":"Br J Haematol"},{"key":"2174_CR179","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmhg.2016.02.001","volume":"17","author":"RM Shawky","year":"2016","unstructured":"Shawky RM, Elsayed SM (2016) Treatment options for patients with Gaucher disease. Egyptian Journal of Medical Human Genetics 17:281\u2013285","journal-title":"Egyptian Journal of Medical Human Genetics"},{"key":"2174_CR180","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/jmedgenet-2012-101070","volume":"49","author":"RE Venier","year":"2012","unstructured":"Venier RE, Igdoura SA (2012) Miglustat as a therapeutic agent: prospects and caveats. J Med Genet 49:591\u2013597. https:\/\/doi.org\/10.1136\/jmedgenet-2012-101070","journal-title":"J Med Genet"},{"key":"2174_CR181","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA (2010) Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35:613\u2013620","journal-title":"Drugs Future"},{"key":"2174_CR182","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1023\/a:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513\u2013526. https:\/\/doi.org\/10.1023\/a:1025902113005","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR183","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JF, van Weely S, Zimran A (2007) Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 110:2296\u20132301. https:\/\/doi.org\/10.1182\/blood-2007-02-075960","journal-title":"Blood"},{"key":"2174_CR184","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.24877","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M et al (2017) Outcomes after 18 months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: the phase 3 ENGAGE trial. Am J Hematol 92:1170\u20131176. https:\/\/doi.org\/10.1002\/ajh.24877","journal-title":"Am J Hematol"},{"key":"2174_CR185","doi-asserted-by":"publisher","unstructured":"Limgala RP, Goker-Alpan O (2020) Effect of substrate reduction therapy in comparison to enzyme replacement therapy on immune aspects and bone involvement in Gaucher disease. Biomolecules 10. https:\/\/doi.org\/10.3390\/biom10040526","DOI":"10.3390\/biom10040526"},{"key":"2174_CR186","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/jrpp.JRPP_18_24","volume":"7","author":"A Nabizadeh","year":"2018","unstructured":"Nabizadeh A, Amani B, Kadivar M, Toroski M, Asl AA, Bayazidi Y, Mojahedian M, Davari M (2018) The clinical efficacy of imiglucerase versus eliglustat in patients with Gaucher\u2019s disease type 1: a systematic review. J Res Pharm Pract 7:171\u2013177. https:\/\/doi.org\/10.4103\/jrpp.JRPP_18_24","journal-title":"J Res Pharm Pract"},{"key":"2174_CR187","first-page":"274","volume":"43","author":"LL Bennett","year":"2018","unstructured":"Bennett LL, Fellner C (2018) Pharmacotherapy of Gaucher disease: current and future options. P T 43:274\u2013309","journal-title":"P T"},{"key":"2174_CR188","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22:119\u2013126. https:\/\/doi.org\/10.1359\/jbmr.061004","journal-title":"J Bone Miner Res"},{"key":"2174_CR189","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C (2013) Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 36:543\u2013553. https:\/\/doi.org\/10.1007\/s10545-012-9528-4","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR190","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, investigators ICGGIGRN (2021) Gaucher disease type 1 patients from the ICGG Gaucher registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab 132:100\u2013111. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.295","journal-title":"Mol Genet Metab"},{"key":"2174_CR191","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2018.11.004","volume":"126","author":"KC Potnis","year":"2019","unstructured":"Potnis KC, Flueckinger LB, Ha CI, Upadia J, Frush DP, Kishnani PS (2019) Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy. Mol Genet Metab 126:157\u2013161. https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.004","journal-title":"Mol Genet Metab"},{"key":"2174_CR192","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90:52\u201360. https:\/\/doi.org\/10.1097\/MD.0b013e3182057be4","journal-title":"Medicine (Baltimore)"},{"key":"2174_CR193","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/jch.13475","volume":"21","author":"M Shani","year":"2019","unstructured":"Shani M, Lustman A, Vinker S (2019) Adherence to oral antihypertensive medications, are all medications equal? J Clin Hypertens (Greenwich) 21:243\u2013248. https:\/\/doi.org\/10.1111\/jch.13475","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2174_CR194","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/diacare.27.5.1218","volume":"27","author":"JA Cramer","year":"2004","unstructured":"Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes Care 27:1218\u20131224. https:\/\/doi.org\/10.2337\/diacare.27.5.1218","journal-title":"Diabetes Care"},{"key":"2174_CR195","unstructured":"Medicine NLo (2018) Safety and efficacy of eliglustat with or without imiglucerase in pediatric patients with Gaucher disease (GD) type 1 and type 3 (ELIKIDS)"},{"key":"2174_CR196","unstructured":"Kane MK, Dean L (2020) Eliglustat therapy and CYP2D6 genotype National Center for Biotechnology Information (US), Bethesda (MD)"},{"key":"2174_CR197","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10545-012-9515-9","volume":"36","author":"RO Brady","year":"2013","unstructured":"Brady RO, Yang C, Zhuang Z (2013) An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain. J Inherit Metab Dis 36:451\u2013454. https:\/\/doi.org\/10.1007\/s10545-012-9515-9","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR198","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","volume":"21","author":"JB Eisengart","year":"2019","unstructured":"Eisengart JB, Pierpont EI, Kaizer AM, Rudser KD, King KE, Pasquali M, Polgreen LE, Dickson PI, Le SQ, Miller WP et al (2019) Intrathecal enzyme replacement for Hurler syndrome: biomarker association with neurocognitive outcomes. Genet Med 21:2552\u20132560. https:\/\/doi.org\/10.1038\/s41436-019-0522-1","journal-title":"Genet Med"},{"key":"2174_CR199","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clim.2018.09.003","volume":"197","author":"A Cherukuri","year":"2018","unstructured":"Cherukuri A, Cahan H, de Hart G, Van Tuyl A, Slasor P, Bray L, Henshaw J, Ajayi T, Jacoby D, O\u2019Neill CA et al (2018) Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: results from a phase 1\/2 study. Clin Immunol 197:68\u201376. https:\/\/doi.org\/10.1016\/j.clim.2018.09.003","journal-title":"Clin Immunol"},{"key":"2174_CR200","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/s0140-6736(95)91037-9","volume":"345","author":"CE Hollak","year":"1995","unstructured":"Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher\u2019s disease. Lancet 345:1474\u20131478. https:\/\/doi.org\/10.1016\/s0140-6736(95)91037-9","journal-title":"Lancet"},{"key":"2174_CR201","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1194\/jlr.M021261","volume":"53","author":"SD Larsen","year":"2012","unstructured":"Larsen SD, Wilson MW, Abe A, Shu L, George CH, Kirchhoff P, Showalter HD, Xiang J, Keep RF, Shayman JA (2012) Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 53:282\u2013291. https:\/\/doi.org\/10.1194\/jlr.M021261","journal-title":"J Lipid Res"},{"key":"2174_CR202","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1098\/rstb.2003.1279","volume":"358","author":"FM Platt","year":"2003","unstructured":"Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci 358:947\u2013954. https:\/\/doi.org\/10.1098\/rstb.2003.1279","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2174_CR203","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.21491","volume":"64","author":"R Schiffmann","year":"2008","unstructured":"Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik IN, Benko W, Timmons M, Ries M et al (2008) Randomized, controlled trial of miglustat in Gaucher\u2019s disease type 3. Ann Neurol 64:514\u2013522. https:\/\/doi.org\/10.1002\/ana.21491","journal-title":"Ann Neurol"},{"key":"2174_CR204","first-page":"46","volume":"124","author":"JA Shayman","year":"2013","unstructured":"Shayman JA (2013) The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc 124:46\u201360","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"2174_CR205","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","volume":"117","author":"M Balwani","year":"2016","unstructured":"Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N (2016) Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab 117:95\u2013103. https:\/\/doi.org\/10.1016\/j.ymgme.2015.09.002","journal-title":"Mol Genet Metab"},{"key":"2174_CR206","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/0091270010372387","volume":"51","author":"MJ Peterschmitt","year":"2011","unstructured":"Peterschmitt MJ, Burke A, Blankstein L, Smith SE, Puga AC, Kramer WG, Harris JA, Mathews D, Bonate PL (2011) Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 51:695\u2013705. https:\/\/doi.org\/10.1177\/0091270010372387","journal-title":"J Clin Pharmacol"},{"key":"2174_CR207","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","volume":"14","author":"MJ Peterschmitt","year":"2019","unstructured":"Peterschmitt MJ, Freisens S, Underhill LH, Foster MC, Lewis G, Gaemers SJM (2019) Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1. Orphanet J Rare Dis 14:128. https:\/\/doi.org\/10.1186\/s13023-019-1085-6","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR208","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/mt.2016.53","volume":"24","author":"J Marshall","year":"2016","unstructured":"Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA et al (2016) CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther 24:1019\u20131029. https:\/\/doi.org\/10.1038\/mt.2016.53","journal-title":"Mol Ther"},{"key":"2174_CR209","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.ymgme.2020.12.229","volume":"132","author":"R Schiffmann","year":"2021","unstructured":"Schiffmann R, Cox T, Dedieu J-F, Sebastiaan G, Hennermann JB, Ida H, Mengel E, Mistry PK, Musholt PB, Sharma J et al (2021) Venglustat combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3. Mol Genet Metab 132:S95","journal-title":"Mol Genet Metab"},{"key":"2174_CR210","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1139\/o66-138","volume":"44","author":"R Hobkirk","year":"1966","unstructured":"Hobkirk R, Nilsen M, Purre E (1966) Peripheral interconversion of phenolic steroids in the human. Can J Biochem 44:1211\u20131220. https:\/\/doi.org\/10.1139\/o66-138","journal-title":"Can J Biochem"},{"key":"2174_CR211","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s0065-2571(64)80024-8","volume":"2","author":"G Weber","year":"1964","unstructured":"Weber G, Henry MC, Wagle SR, Wagle DS (1964) Correlation of enzyme activities and metabolic pathways with growth rate of hepatomas. Adv Enzyme Regul 2:335\u2013346. https:\/\/doi.org\/10.1016\/s0065-2571(64)80024-8","journal-title":"Adv Enzyme Regul"},{"key":"2174_CR212","unstructured":"Blum A (n.d.) Gene therapy for Gaucher disease: AAV, Lentivirus, & MoreNational Gaucher Foundation. https:\/\/www.gaucherdisease.org\/blog\/gene-therapy-for-gaucher-disease-aav-lentivirus-more\/ Accessed 26 April 2021"},{"key":"2174_CR213","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GH Maegawa","year":"2009","unstructured":"Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, Tang L, Kornhaber GJ, Hamuro Y, Clarke JT et al (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284:23502\u201323516. https:\/\/doi.org\/10.1074\/jbc.M109.012393","journal-title":"J Biol Chem"},{"key":"2174_CR214","doi-asserted-by":"publisher","unstructured":"Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV (2017) Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse 71. https:\/\/doi.org\/10.1002\/syn.21967","DOI":"10.1002\/syn.21967"},{"key":"2174_CR215","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M et al (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137:1481\u20131495. https:\/\/doi.org\/10.1093\/brain\/awu020","journal-title":"Brain"},{"key":"2174_CR216","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","volume":"35","author":"Z Luan","year":"2013","unstructured":"Luan Z, Li L, Higaki K, Nanba E, Suzuki Y, Ohno K (2013) The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev 35:317\u2013322. https:\/\/doi.org\/10.1016\/j.braindev.2012.05.008","journal-title":"Brain Dev"},{"key":"2174_CR217","doi-asserted-by":"publisher","unstructured":"Istaiti M, Revel-Vilk S, Becker-Cohen M, Dinur T, Ramaswami U, Castillo-Garcia D, Ceron-Rodriguez M, Chan A, Rodic P, Tincheva RS et al (2021) Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26131","DOI":"10.1002\/ajh.26131"},{"key":"2174_CR218","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","volume":"3","author":"A Narita","year":"2016","unstructured":"Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, Fukuda C, Kubota N, Takayama R, Shigematsu H et al (2016) Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol 3:200\u2013215. https:\/\/doi.org\/10.1002\/acn3.292","journal-title":"Ann Clin Transl Neurol"},{"key":"2174_CR219","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ejp.1538","volume":"24","author":"L Pawlinski","year":"2020","unstructured":"Pawlinski L, Krawczyk M, Fiema M, Tobor E, Kiec-Wilk B (2020) Dual-action ambroxol in treatment of chronic pain in Gaucher disease. Eur J Pain 24:992\u2013996. https:\/\/doi.org\/10.1002\/ejp.1538","journal-title":"Eur J Pain"},{"key":"2174_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2019.102402","volume":"81","author":"SY Chu","year":"2020","unstructured":"Chu SY, Chien CC, Hwu WL, Wang PJ, Chien YH (2020) Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant. Blood Cells Mol Dis 81:102402. https:\/\/doi.org\/10.1016\/j.bcmd.2019.102402","journal-title":"Blood Cells Mol Dis"},{"key":"2174_CR221","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s10038-019-0704-3","volume":"65","author":"W Jiang","year":"2020","unstructured":"Jiang W, Yi M, Maegawa GHB, Zhang H (2020) Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease. J Hum Genet 65:345\u2013349. https:\/\/doi.org\/10.1038\/s10038-019-0704-3","journal-title":"J Hum Genet"},{"key":"2174_CR222","doi-asserted-by":"publisher","unstructured":"Kirkegaard T, Gray J, Priestman DA, Wallom KL, Atkins J, Olsen OD, Klein A, Drndarski S, Petersen NH, Ingemann L et al (2016) Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci Transl Med 8:355ra118.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aad9823","DOI":"10.1126\/scitranslmed.aad9823"},{"key":"2174_CR223","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ebiom.2018.11.037","volume":"38","author":"CK Fog","year":"2018","unstructured":"Fog CK, Zago P, Malini E, Solanko LM, Peruzzo P, Bornaes C, Magnoni R, Mehmedbasic A, Petersen NHT, Bembi B et al (2018) The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase. EBioMedicine 38:142\u2013153. https:\/\/doi.org\/10.1016\/j.ebiom.2018.11.037","journal-title":"EBioMedicine"},{"key":"2174_CR224","unstructured":"Radke V (2021) FDA denies approval of arimoclomol for the treatment of Niemann-Pick type C check rare"},{"key":"2174_CR225","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10545-016-9974-5","volume":"39","author":"JB Hennermann","year":"2016","unstructured":"Hennermann JB, G\u00f6kce S, Solyom A, Mengel E, Schuchman EH, Simonaro CM (2016) Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis 39:831\u2013837. https:\/\/doi.org\/10.1007\/s10545-016-9974-5","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217780","volume":"14","author":"AN Crivaro","year":"2019","unstructured":"Crivaro AN, Mucci JM, Bondar CM, Ormazabal ME, Ceci R, Simonaro C, Rozenfeld PA (2019) Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher disease. PLoS ONE 14:e0217780. https:\/\/doi.org\/10.1371\/journal.pone.0217780","journal-title":"PLoS ONE"},{"key":"2174_CR227","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn.100057","volume":"36","author":"O Dean","year":"2011","unstructured":"Dean O, Giorlando F, Berk M (2011) N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 36:78\u201386. https:\/\/doi.org\/10.1503\/jpn.100057","journal-title":"J Psychiatry Neurosci"},{"key":"2174_CR228","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1179\/135100009X392539","volume":"14","author":"S Whillier","year":"2009","unstructured":"Whillier S, Raftos JE, Chapman B, Kuchel PW (2009) Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. Redox Rep 14:115\u2013124. https:\/\/doi.org\/10.1179\/135100009X392539","journal-title":"Redox Rep"},{"key":"2174_CR229","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","volume":"36","author":"MJ Holmay","year":"2013","unstructured":"Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, \u00d6z G, Cloyd JC, Tuite PJ (2013) N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36:103\u2013106. https:\/\/doi.org\/10.1097\/WNF.0b013e31829ae713","journal-title":"Clin Neuropharmacol"},{"key":"2174_CR230","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles LD, Tuite PJ, \u00d6z G, Mishra UR, Kartha RV, Sullivan KM, Cloyd JC, Terpstra M (2018) Repeated-dose oral N-acetylcysteine in Parkinson\u2019s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol 58:158\u2013167. https:\/\/doi.org\/10.1002\/jcph.1008","journal-title":"J Clin Pharmacol"},{"key":"2174_CR231","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.ymgme.2018.12.201","volume":"126","author":"RV Kartha","year":"2019","unstructured":"Kartha RV, Joers J, Terluk M, Tuite P, Mishra U, Rudser K, Oz G, Weinreb NJ, Jarnes-Utz J, Cloyd JC (2019) Preliminary N-acetylcysteine results for LDN 6722 - role of oxidative stress and inflammation in Gaucher disease type 1: potential use of antioxidant anti-inflammatory medications. Mol Genet Metab 126:S82. https:\/\/doi.org\/10.1016\/j.ymgme.2018.12.201","journal-title":"Mol Genet Metab"},{"key":"2174_CR232","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.ymgme.2019.11.207","volume":"129","author":"RV Kartha","year":"2020","unstructured":"Kartha RV, Terluk M, Kumar T, Zayed H, Doss GP, Cloyd J (2020) Synergistic chaperone activity of N-acetylcysteine and its metabolite L-cysteine in Gaucher disease. Mol Genet Metab 129:S84. https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.207","journal-title":"Mol Genet Metab"},{"key":"2174_CR233","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10545-013-9668-1","volume":"37","author":"L Matalonga","year":"2014","unstructured":"Matalonga L, Arias A, Coll MJ, Garcia-Villoria J, Gort L, Ribes A (2014) Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. J Inherit Metab Dis 37:439\u2013446. https:\/\/doi.org\/10.1007\/s10545-013-9668-1","journal-title":"J Inherit Metab Dis"},{"key":"2174_CR234","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/j.1552-4604.1990.tb01862.x","volume":"30","author":"S Greenberg","year":"1990","unstructured":"Greenberg S, Frishman WH (1990) Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 30:596\u2013608. https:\/\/doi.org\/10.1002\/j.1552-4604.1990.tb01862.x","journal-title":"J Clin Pharmacol"},{"key":"2174_CR235","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.1038\/srep10903","volume":"5","author":"M de la Mata","year":"2015","unstructured":"de la Mata M, Cot\u00e1n D, Oropesa-\u00c1vila M, Garrido-Maraver J, Cordero MD, Villanueva Paz M, Delgado Pav\u00f3n A, Alcocer-G\u00f3mez E, de Lavera I, Ybot-Gonz\u00e1lez P et al (2015) Pharmacological chaperones and coenzyme Q10 treatment improves mutant \u03b2-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease. Sci Rep 5:10903. https:\/\/doi.org\/10.1038\/srep10903","journal-title":"Sci Rep"},{"key":"2174_CR236","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13023-017-0574-8","volume":"12","author":"M de la Mata","year":"2017","unstructured":"de la Mata M, Cot\u00e1n D, Oropesa-\u00c1vila M, Villanueva-Paz M, de Lavera I, \u00c1lvarez-C\u00f3rdoba M, Luz\u00f3n-Hidalgo R, Su\u00e1rez-Rivero JM, Tiscornia G, S\u00e1nchez-Alc\u00e1zar JA (2017) Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease. Orphanet J Rare Dis 12:23. https:\/\/doi.org\/10.1186\/s13023-017-0574-8","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR237","doi-asserted-by":"crossref","unstructured":"Corbau R, Miranda CJ, Comper F, Kalcheva P, Chisari E, Cocita C, Correia S, Pandya J, Liou B, Northcott N et al (2021) FLT201: an AAV-mediated gene therapy for type 1 Gaucher disease designed to target difficult to reach tissues world symposium 2021","DOI":"10.1016\/j.ymgme.2020.12.050"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-021-02174-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:12:11Z","timestamp":1648210331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-021-02174-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":237,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1007\/s00109-021-02174-z","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}